Plasma levels of TNF and IL-10 have been associated with therapy outcome in haematological malignancies and are influenced by genetic variation due to germline polymorphisms within the TNF and IL-10 genes. Different TNF and IL-10 genetic polymorphisms might therefore also correlate with clinical outcome in childhood acute lymphoblastic leukaemia (ALL). We analysed the association of TNF and IL-10 polymorphisms with response to initial treatment and risk of relapse in 135 children with ALL, treated according to Berlin-Frankfurt-Mü nster (BFM) protocols. Our data showed a protective effect from prednisone poor response in patients with the IL-10 G/G genotype, whereas no association of the risk of relapse and IL-10 genotype was found. In the total study group, subjects expressing the TNF2 allele neither showed a statistically significant general association with prednisone response nor with risk of relapse compared to subjects homozygous for the TNF1 allele. Nevertheless, we did find a higher risk of relapse in poor prednisone responders expressing the TNF2 allele compared to poor prednisone responders not expressing the TNF2 allele. We conclude that IL-10 genotype might influence prednisone response in patients with childhood ALL, whereas TNF genotype seems to influence the risk of relapse in high risk ALL patients.
Introduction
Over the last two decades clinical trials have tried intensively to identify prognostic factors for treatment outcome in childhood acute lymphoblastic leukaemia (ALL). The prognostic factors now mostly include clinical and biological characteristics that are assessable at diagnosis as well as early treatment response. 1 In 1983 the BFM study group started to evaluate the early response to initial prednisone treatment as a predictive factor for treatment outcome (prednisone response). Prednisone response is an in vivo resistance test with a high predictive value in childhood ALL, treated according to the ALL-BFM treatment protocols. [2] [3] [4] [5] Many international studies confirmed the prognostic significance of inadequate early reduction of leukaemic blasts. [6] [7] [8] [9] [10] Prednisone response is defined by the peripheral blast count on day 8 of treatment. It is considered as good, if the peripheral blast count is Ͻ1000 blasts/l, whereas it is poor, if a patient shows у1000 blasts/l on day 8 of treatment. In the ALL-BFM 90 study, prednisone good responders had a median 8-year event-free survival (EFS) of 82% in contrast to prednisone poor responders, who showed an EFS of only 34%. 11 The biological background of prednisone response is still unknown. However, investigations with respect to glucocorticoid receptors (GR), 12 distribution of GR isoforms, 13, 14 genetic polymorphisms 15, 16 and proteins being involved in the activation of the GR 17 all attributed in identifying the cause of glucocorticoid resistance.
Tumour necrosis factor (TNF) is a cytokine with pleiotropic biological activities including the induction of programmed cell death and the regulation of immune cell proliferation and differentiation. 18, 19 TNF may also influence the glucocorticoid-induced transcriptional activity of the glucocorticoid receptor gene. 20 The TNF gene is located on chromosome 6p21 within the MHC class III region. A genetic polymorphism at nucleotide position −308 within the promoter region of the TNF gene has been described and is supposed to affect the consensus sequence for the binding site of the transcription factor AP-2. 21, 22 Guanine at position −308 defines the TNF1 allele and adenine the less common TNF2 allele that has been shown to correlate with a higher protein expression of TNF. Besides a worse outcome of autoimmune and infectious diseases, 23, 24 TNF plasma levels have been associated with an adverse outcome in solid and lymphoid malignancies. [25] [26] [27] [28] Furthermore, TNF genotype was correlated with steroid-resistant rejection episodes following renal transplantation. 29 IL-10 is a cytokine predominantly expressed in B lymphocytes. It is involved in the terminal differentiation of B cells into plasma cells and has been shown to be a growth factor for B cell malignancies. 30, 31 In addition, IL-10 can be considered as a natural immunosuppressant of TNF. 32 The IL-10 gene is located on chromosome 1q31-q32. A polymorphism at nucleotide position −1082 within the IL-10 gene promotor region is thought to have an influence on IL-10 plasma levels. Adenine at nucleotide position −1082 defines the IL-10A* allele, whereas guanine at the same position defines the less common IL-10G* allele. Patients homozygous for the IL-10G* allele were shown to express high IL-10 plasma levels. 33 The clinical relevance of high IL-10 plasma levels (and thus of the genetic polymorphism at nucleotide position −1082 within the IL-10 gene) is still contradictory. Franchimont et al 20 have shown that the binding capacity for dexamethasone can be up-regulated by high IL-10 production. 20 Other studies found a correlation between the polymorphic IL-10 alleles and severity of chronic inflammatory and rheumatoid diseases [34] [35] [36] [37] [38] [39] as well as treatment outcome in haematological malignancies 40 and immunologic, infectious and atopic conditions. 33, [41] [42] [43] Furthermore, IL-10 genotype was associated with rejection episodes following liver, heart and renal transplant. 29, 32, 44, 45 In a previous study with 64 relapsed and 64 successfully treated childhood ALL patients we could not find a correlation between the TNF polymorphism at nucleotide position −308 and risk of relapse. 46 However, due to the matching criteria the study only included patients with standard or intermediate risk childhood B-precursor ALL. We suggested further investigating the polymorphism in a group of childhood ALL patients that included different immunophenotypes and all clinical risk groups, especially high risk patients with poor prednisone response. In the present study, we therefore genotyped a case-control study group of 135 patients with childhood acute lymphoblastic leukaemia, frequency matched for initial WBC, for the above described genetic polymorphisms within the TNF and IL-10 genes (TNF −308 and IL-10 −1082 ) in order to assess the predictive potential of the polymorphisms with regard to prednisone response and risk of relapse in childhood ALL.
Materials and methods

Patients and study design
Our study was designed as a frequency matched case-control study. The study utilizes spare unstained peripheral blood or bone marrow remission samples and clinical data from ALL patients of the ALL-BFM 86 and ALL-BFM 90 multicentre trials. Design, conduct, analysis, and results of the ALL-BFM 86 and ALL-BFM 90 trials have been meticulously described previously. 11, 47 In both trials patients were treated within three different risk groups (standard, intermediate and high risk). Stratification into the risk groups was made predominantly according to the leukaemic cell mass estimate (so-called risk factor, a composite variable calculated from the initial blast count in the peripheral blood and the sizes of liver and spleen below the costal margin) and initial treatment response. Eventfree survival (EFS) as well as the risk of relapse differs profoundly between the three risk groups. The cases in our study were 45 patients with poor response to initial prednisone treatment controls were 90 patients with good prednisone response, randomly selected by employing frequency matching according to initial white blood count (WBC) category. The WBC categories were defined as р50 000, Ͼ50 000-100 000 and Ͼ100 000 leukocytes/l ( Table 1 ). All patients who did not die from progressive disease or relapsed ALL had Table 1 Characteristics of 135 patients with prednisone poor-response (cases) or prednisone good-response (controls) from the case-control study sample of 135 patients selected from the ALL-BFM 86 and ALL-BFM 90 studies Prednisone poor response Prednisone good response P a n (%) n (%) a minimum follow-up of 5 years. Similarity of treatment between cases and controls within the different trials was ensured by matching the patients for the treatment arm within the risk group of the respective study. Controls had to have a minimum follow-up of 5 years. In the case of relapses occurring later than 5 years after initial diagnosis, the follow-up for the control subject had to be at least as long as the time between initial diagnosis and date of relapse in the case subject. If more than one control subject was available, the subject with the closest initial WBC at diagnosis with reference to the case subject was chosen. The patient group of this casecontrol study has already been described in detail. 16 
Genotype analysis
Genomic DNA was isolated from bone marrow or peripheral blood smears. Genotypes for TNF and IL-10 were determined by polymerase chain reaction (PCR)-based restriction fragment length polymorphism analysis. The PCR product was analysed on a 3% Nusieve gel after digestion with NcoI (TNF) or MnlI (IL-10) overnight. Primer sequences for TNF were: 5Ј-AGG CAA TAG GTT TTG AGG GCC AT-3Ј (forward) and 5Ј-TCC TCC CTG CTC CGA TTC CG-3Ј (reverse). In the case of the presence of the TNF1 allele, the amplified 107 bp fragment from the TNF promotor was cut into two fragments of 87 and 20 bp, a fragment amplified from TNF2 remained uncut. 26 Primer sequences for IL-10 were: 5Ј-CTC GCT GCA ACC CAA CTG GC-3Ј (forward) and 5Ј-TCT TAC CTA TCC CTA CTT CC-3Ј (reverse). In the case of the presence of the IL-10G* allele, the amplified 139 bp fragment from the IL-10 promotor wass cut into two fragments of 106 and 33 bp, a fragment amplified from IL-10A* remained uncut. 33 
Cloning, sequencing and alignment
The analysis of the IL-10 PCR repetitively showed double bands for the digested as well as the undigested products on the agarose gels. To ensure the specificity of our PCR we inserted an uncut PCR product into a TOPO plasmid vector and cloned the product by transforming chemically competent Escherichia coli cells. Sequencing of four different products revealed a deletion of six to nine base pairs within our products. According to the genetic sequence of the IL-10 gene as published by Eskdale et al, 48 
Statistical analysis
Frequencies were calculated for descriptive purposes. Differences in the distribution of categorical variables were analysed by 2 or Fisher's exact test. The association of TNF and IL-10 genotypes and prednisone response, risk of relapse, or other important prognostic variables (sex, age at diagnosis, initial WBC, initial peripheral blast count, immunophenotype) was examined by univariate and multivariate logistic regression analyses to calculate odds ratios (OR) and their 95% confidence intervals (CI). Genotypes and genotype combinations were used as categorical variables in the analyses. The power of this case-control study to detect an odds ratio of у2.9 for the IL-10 genotype and an of у2.8 for the TNF genotype is Ͼ80%. The power to detect an odds ratio of у3.3 for the TNF genotype and of у3.5 for the IL-10 genotype is Ͼ90%. Computations were performed using SAS software (SAS-PC Version 6.04; SAS Institute, Cary, NC, USA). The hypothesis being that high plasma levels of IL-10 are associated with good prednisone response, we used the combined category of IL-10 A/A and IL-10 A/G as reference category for the correlation of IL-10 genotype and prednisone response, because Turner et al 49 described that only in those patients not expressing the IL-10A* allele can high IL-10 plasma levels be found. Table 1 shows the distribution of the characteristics of all patients investigated. Within the total number of 135 patients, 90 patients showed the TNF1/TNF1 genotype, 45 patients the TNF1/TNF2 genotype. None of the study subjects was homozygous for TNF2 (TNF1/TNF1 = 66.7%, TNF1/TNF2 = 33.3%, TNF2/TNF2 = 0.0%). This distribution was similar to the distribution of the TNF genotype observed by Demeter et al 28 in a healthy German control sample. Patients in our study who had a heterozygous TNF genotype (n = 45) were not identical to those patients clinically responding poorly to prednisone treatment (n = 45). Overall, we did not observe a significant correlation between TNF genotype and prednisone response or risk of relapse (OR = 2.11, 95% CI = 0.90-4.96, P = 0.09 and OR = 1.58, 95% CI = 0.65-3.83, P = 0.31 in multivariate analyses with the low producing TNF1/TNF1 genotype as reference category, Tables 2 and 3 ). The hypothesis being that the TNF2 allele might be associated with poor treatment outcome, we further evaluated TNF genotype exclusively in patients who had at least one known clinical risk factor for poor treatment outcome. The risk factors evaluated included high initial white blood count (WBC), immunophenotype and prednisone response (Table 4 ). This subgroup analysis revealed that there was an overall tendency for high risk of relapse in patients who had one of the investigated clinical risk factors and the TNF1/TNF2 genotype, compared to the same clinical subgroup of patients with homozygous TNF1/TNF1 genotype. Only poor responders with the TNF1/TNF2 genotype, though, showed a 14.5-fold increased risk of relapse that was statistically significant compared to those poor responders with the homozygous TNF1/TNF1 genotype (95% CI = 1.31-161.12, P = 0.03 in multivariate analysis). These results that suggest an association of TNF genotype and risk of relapse in childhood ALL have to be interpreted carefully considering that our study was primarily designed as a case-control study for prednisone response.
Results and discussion
Leukemia
The IL-10 genotype distribution in our study group was as follows: 38 patients were found to be homozygous for the IL-10A* allele, 72 patients displayed the heterozygous IL-10 A/G genotype and 25 patients were homozygous for the IL-10G* allele (IL-10 A/A = 28.1%, IL-10 A/G = 53.3%, IL-10 G/G = 18.5%). The allele frequencies were 54.8% (IL-10A*) and 
45.2% (IL-10G*)
. IL-10 genotype distribution was in a similar range as observed in 78 healthy health care workers in the UK, even though there was a slightly lower percentage of the heterozygous genotype (45%) and a slightly higher percentage of the homozygous IL-10 G/G genotype (27%) in this control group. 50 The distribution of the IL-10 genotype in prednisone good responders and prednisone poor responders is shown in Table 5 . There was an overall protective effect from poor prednisone response in patients showing the IL-10 G/G genotype compared to the reference category (OR = 0.32, 95% CI = 0.10-0.99, P = 0.049), whereas we found no association of IL-10 genotype and risk of relapse in childhood ALL (OR = 1.10, 95% CI = 0.43-2.81, P = 0.837, Table 6 ). Subgroup analysis for IL-10 was performed and included haplotype and immunophenotype. Interestingly, the association of IL-10 50 for example, did not find a correlation between genotype and disease susceptibility nor resistance in primary sclerosing cholangitis, whereas Tagore et al 35 showed that there was a protective effect of high IL-10 levels against inflammatory bowel diseases. Edwards-Smith et al, 33 on the other hand, reported that high IL-10 levels predicted a poor treatment outcome using interferon-␣ for treatment of hepatitis C. Following solid organ transplantation, IL-10 and TNF have been shown to be associated with acute rejections and steroid resistance. 29 , 45 Sankaran et al 29 found the least rejection episodes in patients expressing low IL-10 and low TNF, whereas high producers of both cytokines had the highest number of rejections. In graft-versus-host disease (GVHD) following bone marrow transplantation (BMT), Middleton et al 32 found no association with TNF −308 polymorphism, whereas there was an association of severity of GVHD and homozygous d3 allele of the TNFd microsatellite as well as IL-10 −1064 polymorphism. The IL-10 −1064 polymorphism refers to the same genetic location as the IL-10 −1082 polymorphism analysed in this study. In a large cohort of 144 matched sibling donor/recipient pairs they could later show that IL-10 and TNFd3 polymorphism is not only associated with GVHD after BMT but also with early mortality. 51 Our data suggest an association of treatment outcome in childhood ALL and IL-10 and TNF genotype. Treatment within the ALL-BFM 86 and ALL-BFM 90 trials was adapted according to prednisone response. Patients showing poor response were stratified into the high risk group and therefore underwent a more intensive treatment. Even though we controlled for treatment intensity in multivariate analysis, it cannot be ruled out that there might be a residual confounding of treatment intensity on our results. These data, nevertheless, underline that TNF and IL-10 seem to have influence on treatment outcome in haematological conditions. To answer the question of clinical importance in childhood acute lymphoblastic leukaemia, large prospective studies will have to be performed.
In conclusion, our results suggest a correlation between the IL-10 genotype and prednisone response in childhood ALL. Patients displaying the IL-10 G/G genotype might have a lower risk for poor prednisone response. We could not find a generally important role of the investigated genetic TNF polymorphism with regard to prednisone response or risk of relapse in childhood ALL. High risk patients with childhood ALL might, nevertheless, have a higher risk of relapse if they display the TNF1/TNF2 genotype.
